Nancy Stagliano

Nancy has always been fascinated by how the brain works. “Of all parts of the body, to me it is the most interesting and the most complex,” she explains. “I think the brain is the final frontier.”

Nancy has always been driven by her love of science and medicine, receiving a PhD in neuroscience, and degrees in both biomedical and electrical engineering, followed by a postdoc at Harvard Medical School. She holds numerous patents and published works in respected journals.

“While some people have a clear sense of what they want to do, most don’t,” she says. “I certainly didn’t. When opportunity knocks, open your mind to new experiences.”

Nancy is passionate about building high performing teams dedicated to finding new therapies that make a difference for patients. “Success to me is defined by getting a therapeutic to patients,” she says. “I think my crowning career achievement to-date is the work I did with True North.” True North (now owned by Sanofi) is poised to gain FDA approval for their orphan drug to treat cold agglutinin disease, a rare condition in which the body’s immune system mistakenly attacks and destroys its own red blood cells.

During her career, Nancy has been CEO of three successful companies—True North Therapeutics, iPierian, and CytomX Therapeutics

As the CEO and chair at Neuron23, Nancy takes a hands-on approach to building the company, following the science, and mentoring the team.

Nancy serves on the boards of a number of other biotechnology companies, including Pandion Therapeutics and Latigo Biosciences, as well as the not-for-profit organization PanCAN. Nancy is also an entrepreneur in residence at Westlake Village BioPartners.